前三季度98%普通股基上涨 华安医药生物上涨103%

Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]